Published in Cell on March 16, 2012
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | NCT01307267
Phase II, 2nd Line Melanoma - RAND Monotherapy | NCT00612664
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma | NCT00848926
Study of Immune Responses in Patients With Metastatic Melanoma | NCT01416844
Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med (2013) 2.03
Cancer nanomedicines: so many papers and so few drugs! Adv Drug Deliv Rev (2012) 1.66
Meta-analysis of clinical data using human meiotic genes identifies a novel cohort of highly restricted cancer-specific marker genes. Oncotarget (2012) 1.31
Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J Clin Invest (2014) 1.21
A novel cohort of cancer-testis biomarker genes revealed through meta-analysis of clinical data sets. Oncoscience (2014) 1.17
Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. J Immunol (2014) 1.13
Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies. Proc Natl Acad Sci U S A (2013) 1.04
Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy. Oncoimmunology (2012) 0.97
The Mysterious Ways of ErbB2/HER2 Trafficking. Membranes (Basel) (2014) 0.96
Immunotherapy for colorectal cancer. World J Gastroenterol (2013) 0.94
The forgotten tale of immunoglobulin allotypes in cancer risk and treatment. Exp Hematol Oncol (2013) 0.91
Novel immunotherapies for hematologic malignancies. Immunol Rev (2015) 0.90
Nuclear localization of CD26 induced by a humanized monoclonal antibody inhibits tumor cell growth by modulating of POLR2A transcription. PLoS One (2013) 0.88
Impact of the immune system and immunotherapy in colorectal cancer. J Gastrointest Oncol (2015) 0.87
Mechanisms of action of therapeutic antibodies for cancer. Mol Immunol (2015) 0.87
Anti-S100A4 antibody suppresses metastasis formation by blocking stroma cell invasion. Neoplasia (2012) 0.86
Fully human antagonistic antibodies against CCR4 potently inhibit cell signaling and chemotaxis. PLoS One (2014) 0.85
Anti-CD20 therapy induces a memory Th1 response through the IFN-γ/IL-12 axis and prevents protumor regulatory T-cell expansion in mice. Leukemia (2014) 0.83
Selected anti-tumor vaccines merit a place in multimodal tumor therapies. Front Oncol (2012) 0.82
Approaching untargetable tumor-associated antigens with antibodies. Oncoimmunology (2013) 0.80
Targeting of antigens to B lymphocytes via CD19 as a means for tumor vaccine development. J Immunol (2013) 0.79
Synergistic anti-tumor therapy by a comb-like multifunctional antibody nanoarray with exceptionally potent activity. Sci Rep (2015) 0.79
c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity. Cancer Immunol Res (2014) 0.78
Cancer as an immune-mediated disease. Immunotargets Ther (2012) 0.77
Immunotherapeutic approaches to treat multiple myeloma. Hum Vaccin Immunother (2013) 0.77
Development of a high affinity, non-covalent biologic to add functionality to Fabs. Sci Rep (2015) 0.76
Nanocarrier-based immunotherapy in cancer management and research. Immunotargets Ther (2014) 0.76
Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs. J Clin Pharmacol (2015) 0.76
PRL3-zumab, a first-in-class humanized antibody for cancer therapy. JCI Insight (2016) 0.75
IgE immunotherapy against cancer. Curr Top Microbiol Immunol (2015) 0.75
Requirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat established melanoma with chemo-immunotherapy. Cancer Immunol Res (2015) 0.75
Efficient method to optimize antibodies using avian leukosis virus display and eukaryotic cells. Proc Natl Acad Sci U S A (2015) 0.75
Intravital Microscopy Imaging Approaches for Image-Guided Drug Delivery Systems. Curr Drug Targets (2015) 0.75
Parasites and immunotherapy: with or against? J Parasit Dis (2014) 0.75
Natural and non-natural amino-acid side-chain substitutions: affinity and diffraction studies of meditope-Fab complexes. Acta Crystallogr F Struct Biol Commun (2016) 0.75
Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster. Oncotarget (2015) 0.75
A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy. Hum Vaccin Immunother (2015) 0.75
Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms. J Immunol (2017) 0.75
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med (2000) 13.24
Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol (2010) 6.04
Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med (2000) 5.62
The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol (2009) 3.72
Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med (2002) 3.12
Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science (2011) 2.63
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell (2011) 2.14
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell (2011) 2.14
Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov (2011) 1.89
Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol (2009) 1.86
Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood (2001) 1.56
Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res (2011) 1.27
Targeting intracellular oncoproteins with antibody therapy or vaccination. Sci Transl Med (2011) 1.24
Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A (2010) 1.24
T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proc Natl Acad Sci U S A (2010) 1.18
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med (2006) 7.10
Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study. J Bone Joint Surg Am (2003) 1.76
Heat shock protein 90alpha recruits FLIPS to the death-inducing signaling complex and contributes to TRAIL resistance in human glioma. Cancer Res (2007) 0.89
Bone marrow-derived cell-specific chemokine (C-C motif) receptor-2 expression is required for arteriolar remodeling. Arterioscler Thromb Vasc Biol (2009) 0.88
Capillary arterialization requires the bone-marrow-derived cell (BMC)-specific expression of chemokine (C-C motif) receptor-2, but BMCs do not transdifferentiate into microvascular smooth muscle. Angiogenesis (2009) 0.84
Influence of poly(D,L-lactic-co-glycolic acid) microsphere degradation on arteriolar remodeling in the mouse dorsal skinfold window chamber. J Biomed Mater Res A (2009) 0.79